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Arsenic is a well-documented human carcino-
gen and is associated with an increased risk of
human cancers of the skin, lung, and bladder
(Chen et al. 1985; Forkner and McNair-Scott
1931; Kandel and Leroy 1937; Konig et al.
1997; Nriagu 1994; Smith et al. 1992;
Sommers and McManus 1953). Interestingly,
arsenic-containing compounds have been
used for treatment of cancer for hundreds of
years in both traditional Chinese and
Western medicine (Chen et al. 1996, 1997;
Forkner and McNair-Scott 1931; Kandel and
Leroy 1937; Konig et al. 1997). Several
recent studies confirm that arsenic trioxide
appears to be a valuable therapeutic tool for
patients with acute promyelocytic leukemia
(Chen et al. 1996, 1997).
Although arsenic and its modes of
action have been the subject of reviews and
symposia, little data exist regarding specific
mechanism(s) differentiating its action as
a carcinogen to cause cancer and as a
chemotherapeutic agent used in the treatment
of cancer. Recently, our laboratory findings
provided mechanisms of arsenic-induced neo-
plastic cell transformation and arsenic-
induced apoptosis in tumor cells (Bode and
Dong 2000, 2002; Chen et al. 2000a, 2000b;
Huang et al. 1999a, 1999b, 2001) (Figure 1).
Arsenic Induces Cell Transformation
Much of the lack of progress in determining
mechanisms explaining the role of arsenic as a
carcinogen or as a chemotherapeutic agent
has been attributed to the availability of valid
and reproducible animal models. To study
whether arsenite induces cell transformation,
we exposed JB6 Cl 41 cells to arsenite in soft
agar. Anchorage-independent colonies were
observed in the eighth week after arsenite
exposure. Cell transformation can only be
observed in cells exposed to 0.5–25 µM
arsenite, whereas no transformed colonies
were observed at higher concentrations of
arsenite (50–100 µM) because of the toxicity
of arsenic (Huang et al. 1999a, 1999b).
Induction of Apoptosis by Higher
Concentrations of Arsenic
A higher concentration of arsenic appears to
prevent cell transformation by inducing
apoptosis. We showed that treatment of
cells with a relatively higher concentration
(200 µM) of arsenite or arsenate resulted in
apoptosis by 44.5 and 61.5%, respectively
(Chen et al. 2000b).
Differential Activation of Erks and
JNKs by Arsenite
We found that arsenite could induce activa-
tion of both c-Jun NH2-terminal kinases
(JNKs) and extracellular signal-regulated
protein kinases (Erks) (Huang et al. 1999a,
1999b). However, the activation of JNKs
and Erks by arsenite differs in time course
and dose response. During the time course
and dose–response studies, marked Erks acti-
vation could be observed 15 min after expo-
sure and at all dosages studied, but no
significant induction of Erks by arsenite
occurred after a 30-min exposure. In con-
trast, arsenic activation of JNKs was observed
only at a relatively high dosage (>50 µM)
and after 60 min of exposure.
Arsenic Induces AP-1 Activation 
in Cells and AP-1-Luciferase
Transgenic Mice
Using JB6 cells, we found that both arsenite
and arsenate could induce transactivation of
AP-1 (Huang et al. 2001). This induction of
AP-1 activity by arsenic appears to occur
through activation of mitogen-activated pro-
tein (MAP) kinases and protein kinase C
(PKC) because increased AP-1 activity by
arsenite could be blocked by either treating
cells with PD98059, an MAP kinase Erk
kinase (MEK)1 inhibitor, or overexpression
of dominant-negative PKCα (Chen et al.
2000a; Huang 2001). Furthermore, both
arsenite and arsenate could induce transacti-
vation of AP-1 in AP-1-luciferase reporter
transgenic mice (Huang 2001).
Inhibition of Erks Activation Blocks
Arsenic-Induced Cell Transformation
The results described above revealed that
Erks activation by arsenite may be involved
in its cell transformation activity. To test
this possibility, we used dominant-negative
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Arsenic is a well-documented human carcinogen associated with cancers of the skin, lung, liver,
and bladder. Interestingly, arsenic has also been used as an effective chemotherapeutic agent in the
treatment of certain human cancers. However, the mechanisms by which arsenic induces prolifera-
tion of cancer cells or cancer cell death are not well understood. We found that exposure of JB6
P+ cells to low concentrations of arsenic induces cell transformation, whereas higher concentra-
tions of arsenic induce cell apoptosis. Arsenite induces phosphorylation of extracellular signal-reg-
ulated protein kinases (Erks) and c-Jun NH2-terminal kinases (JNKs). Arsenite-induced Erk
activation was markedly inhibited by introduction of dominant-negative Erk2 into cells, whereas
expression of dominant-negative Erk2 did not inhibit JNKs or mitogen-activated protein kinase
Erk kinase 1/2. Furthermore, arsenite-induced cell transformation was blocked in cells expressing
dominant-negative Erk2. In contrast, overexpression of dominant-negative JNK1 increased cell
transformation even though it inhibited arsenite-induced JNK activation. Arsenic also induced
AP-1 and nuclear factor kappa B (NF-κ B) activation. Blocking NF-κ B activation by dominant-
negative inhibitory kappa Βα  inhibited arsenic-induced apoptosis and enhanced arsenic-induced
cell transformation. Arsenic induced activation of JNKs at a similar dose range that was effective
for induction of apoptosis in JB6 cells. In addition, we found that arsenic did not induce p53-
dependent transactivation. Similarly, apoptosis induction was not different between p53 wild-type
(p53+/+) or p53-deﬁcient (p53–/–) cells. In contrast, arsenic-induced apoptosis was almost totally
blocked by expression of a dominant-negative mutant of JNK. Taken together with previous ﬁnd-
ings that p53 mutations are involved in approxmiately 50% of all human cancers and nearly all
chemotherapeutic agents kill cancer cells mainly by apoptotic induction, we suggest that arsenic
may be a useful agent for the treatment of cancers with p53 mutations. These results suggest that
the activation of Erks is required for arsenic-induced cell transformation, whereas the activation of
JNKs and NF-κ B is involved in arsenic-induced apoptosis of JB6 cells. Key words: AP-1, apopto-
sis, arsenic, cell transformation, MAP kinase, NF-κ B, signal transduction. Environ Health
Perspect 110(suppl 5):757–759 (2002).
http://ehpnet1.niehs.nih.gov/docs/2002/suppl-5/757-759dong/abstract.html
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Erk2-K52R stable transfectants (Chen et al.
2000b; Huang 1999a, 1999b). Our results
demonstrate that Erk activation but not
JNK activation is required for arsenite-
induced cell transformation.
Inhibition of JNKs Blocks Arsenic-
Induced Apoptosis
To investigate the role of activation of JNKs
in arsenic-induced apoptosis, we used JB6
cells and a dominant-negative mutant of
JNK1 to test the effects on arsenic-induced
apoptosis (Huang et al. 1999a). Expression of
the dominant-negative mutant JNK1 blocked
induction of apoptosis by arsenite (4%) or
arsenate (7%) compared with vector-trans-
fected control cells (31.5 and 40.5% for
arsenite and arsenate, respectively) (Sommers
and McManus 1953).
p53 Is Not Involved in Induction 
of Apoptosis by Arsenic
Arsenic had no effect on p53-dependent tran-
scription activation in Cl 41 p53 cells treated
with a wide dose range of arsenic (Huang 
et al. 1999a). This suggested that p53 may not
be involved in arsenic-induced apoptosis. This
hypothesis was further tested by studying the
effects of arsenic on two fibroblast cell lines
derived from mouse embryos either contain-
ing wild-type p53 (p53+/+) or deﬁcient in p53
(p53–/–). Results showed that treatment with
arsenite or arsenate results in apoptosis in both
cell lines (Huang et al. 1999a). Therefore,
arsenic may be effective in counteracting drug
resistance in p53-deficient cancers because
arsenic appears to be able to induce apoptosis
in tumor cells independently of p53 activation
and thus could be speciﬁcally directed against
p53-defective cancer cells.
Involvement of PKC in Arsenic-
Induced Signal Transduction
Our recent data show that PKC, upstream
from the MAP kinases, may be involved in
mediating arsenite-induced signal transduc-
tion (Chen et al. 2000a). Translocation of
PKC from the cytosol to the membrane is a
critical step for activation of this enzyme,
and treatment of JB6 cells with arsenite
resulted in an increased translocation of PKC
within 15 min. Inhibition of activation of
PKC blocked both arsenite-induced AP-1
activity and arsenite-induced phosphoryla-
tion of Erks, JNKs, and p38 kinase, suggest-
ing that PKC is required for arsenite-induced
activation of MAP kinases.
Tea Polyphenols Block Arsenic-
Induced Signal Transduction and
Cytotoxicity
Arsenite-induced apoptosis appears to be
important in accounting for its toxicity. Green
tea has been used as a traditional Chinese
remedy for detoxification of arsenite-caused
toxicity. In recent work, we found that tea
polyphenols, (–)-epigallocatechin-3-gallate
(EGCG) and theaflavins, effectively blocked
arsenite-induced apoptosis in JB6 cells and
inhibited arsenite-induced AP-1 transcrip-
tional activation and AP-1 DNA-binding
activity (Chen et al. 2000b). EGCG and
theaﬂavins potently inhibited arsenite-induced
Erk activity but not p38 kinase activity.
PD98059, an inhibitor of Erks, and domi-
nant-negative mutant (DNM)-JNK1 blocked
arsenite-induced apoptosis, whereas DNM-
p38 kinase or SB2020190, an inhibitor of p38
kinase, did not. We conclude that Erks and
JNKs may be involved in arsenite-induced
apoptosis, and the inhibition of arsenite-
induced apoptosis by EGCG and theaﬂavins
may be mediated by a decreased phosphoryla-
tion of Erks and JNKs. Furthermore, these
results provide a possible mechanism explain-
ing the detoxiﬁcation effect of tea on arsenite-
induced toxicity (Chen et al. 2000b).
Blocking NF-κ B Activation Inhibits
Arsenic-Induced Apoptosis
Nuclear factor kappa B (NF-κ B) is a rapidly
induced stress-responsive transcription factor
that may play an important role in arsenic-
induced signal transduction, cell transforma-
tion, and apoptosis (Bode and Dong 2000,
2002). Barchowsky et al. (1996,1999)
reported that arsenic-induced oxidant stress,
H2O2, and superoxide are the predominant
reactive species in endothelia cells and may be
the mediators for the activation of the NF-κ B
pathway. We showed that arsenic induced
activation of NF-κ B in different cell culture
models. Expression of a dominant-negative
inhibitory kappa Βα  blocked arsenic-induced
activation of NF-κ B and apoptosis.
Conclusions
Arsenic is clearly a human carcinogen, but also
acts as a beneficial chemotherapeutic agent.
The lack of information regarding its mecha-
nisms of action has been attributed to the
availability of appropriate animal models. In
the past few years we have established cell cul-
ture models to study arsenic-induced neoplas-
tic cell transformation and apoptosis. Others
have also reported that exposure of arsenic
could induce cell transformation in a rat liver
epithelial cell line (TRL 1215) (Meng and
Meng 2000) or in blast transformation and
DNA synthesis in human lymphocytes (Zhao
et al. 1997). We found that arsenic signifi-
cantly affects speciﬁc signal transduction path-
ways (Figure 1). Our data provided a model
for the role of signaling molecules including
MAP kinases, p53, AP-1, and NF-κ B in
arsenic-induced cell transformation and apop-
tosis. More detailed studies are needed to
determine precise mechanisms of the effects of
arsenic on animals and humans.
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